Fractyl Health (GUTS)
Develops clinical-stage therapies for obesity and type 2 diabetes through the gut and pancreas.
Something off on this page? Send us feedback.
Develops Revita, a procedure in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV gene-therapy platform. Both programs remain clinical-stage and depend on clinical evidence and regulatory pathways.
Develops Revita, a single-procedure therapy in pivotal development for post-GLP-1 weight maintenance. The company describes it as the procedural arm of its obesity portfolio.
Rejuva is the AAV gene-therapy arm. Its lead candidate, RJVA-001, is planned for a first-in-human study in adults with inadequately controlled T2D, subject to site activation.
Headquartered in Burlington, Massachusetts, the founder-led organization has 100 full-time employees, most dedicated to research and development. It operates as a single segment rather than commercial business lines; clinical evidence and regulatory pathways for both programs shape the business at this stage.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jul 1, 2026 | Craig-Hallum | Initiate | Buy | ||
| Jan 30, 2026 | Morgan Stanley | Downgrade | Overweight | Equal Weight | |
| Jan 29, 2026 | Morgan Stanley | Target | $2 | ||
| Dec 19, 2025 | Canaccord Genuity | Target | $8 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $47.1M · Total debt $60.7M · Total assets $82.0M · Shareholders' equity −$1.7M
- Revenue
- $0
- Operating income
- −$19.1M
- Net income
- −$25.5M
No dividends on record.
| Institutions83 holders · as of Mar 31, 2026 | 45.24% | 72.01M shares | |
| Insiders9 holders · as of Jun 15, 2026 | 5.09% | 8.10M shares | |
| Otherremainder | 49.67% | 79.06M shares |
159.18M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Nantahala Capital Management, LLCInstitution | 8.40% | 13.36M | 13Fas of Mar 31, 2026 |
683 Capital Management, LLCInstitution | 4.23% | 6.73M | 13Fas of Mar 31, 2026 |
Ajay RoyanInsiderdirector | 4.05% | 6.45M | Form 4filed Jun 15, 2026 ↗ |
Pale Fire Capital SEInstitution | 3.72% | 5.92M | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 3.48% | 5.53M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 12, 2026 | Ajay Royan | director | +23,000 | $0.8520 |
| Jun 10, 2026 | Harith Rajagopalan | director, officer: Chief Executive Officer | +25,000 | $0.7301 |
| Jun 10, 2026 | Ian Sheffield | director | +35,000 | $0.7294 |
| Jun 10, 2026 | William Bradley | director | +68,493 | $0.7348 |
| Jun 8, 2026 | Weber Lara Smith | officer: Chief Financial Officer | +20,000 | $0.6854 |
- Eli Lilly
Tirzepatide therapies for obesity and type 2 diabetes
- Novo Nordisk (ADR)
Semaglutide therapies for obesity and type 2 diabetes
- Amgen
MariTide Phase 3 program spans obesity and T2D
- Viking Therapeutics
VK2735 Phase 3 obesity program includes adults with T2D
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Fractyl Health | $0.7077 | −0.03% | $112.1M | — | — | — | — |
| Eli Lilly | $1,165.01 | +0.49% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Novo Nordisk (ADR) | $47.45 | +1.49% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Amgen | $442.21 | −0.14% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Viking Therapeutics | $32.98 | −1.55% | $3.91B | — | — | — | — |
| Median | 27.5 | 18.9 | 6.3 | +9.7% |